Skip to main content
SpringerLink
Log in

Treatment of aggressive adult T-cell leukemia/lymphoma: a retrospective study in a hospital located in HTLV-1 highly endemic area

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

A Correction to this article was published on 06 March 2020

This article has been updated

Abstract

Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell neoplasm associated with the human T-cell leukemia virus type-I (HTLV-1); prognosis still remains very poor. We retrospectively reviewed the treatment of 198 patients with acute-, lymphoma- and unfavorable chronic-type ATL (aggressive ATL) diagnosed from 2005 to 2014 in a hospital located in an area of Japan in which HTLV-1 is highly endemic. One-hundred forty-three, and 35 patients were treated using OPEC/MPEC and VCAP-AMP-VECP, respectively. OPEC/MPEC was mainly used until around 2010, and gradually switched to VCAP-AMP-VECP, especially for younger patients. The 2-year overall survival for patients treated by VCAP-AMP-VECP was significantly higher than that using OPEC/MPEC for patients < 70 years old (y.o.), but not for patients ≥ 70 y.o. A less intensive chemotherapy OPEC/MPEC could be performed without reducing dose intensity, even in elderly patients, and its therapeutic outcome is not inferior to that of VCAP-AMP-VECP. It is difficult to draw definite conclusion from this small retrospective study; however, OPEC/MPEC may represent an alternative option for elderly patients with aggressive ATL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Change history

  • 06 March 2020

    In the original publication of the article, Table 5 was published with incorrect contents. The correct Table 5 is given in this correction.

References

  1. Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia–lymphoma. Lancet Oncol. 2014;15(11):e517–e526526.

    Article  CAS  PubMed  Google Scholar 

  2. Uchiyama T, et al. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50(3):481–92.

    Article  CAS  PubMed  Google Scholar 

  3. Katsuya H, et al. Treatment and survival among 1594 patients with ATL diagnosed in the 2000s: a report from the ATL-PI project performed in Japan. Blood. 2015;126:2570–7.

    Article  CAS  PubMed  Google Scholar 

  4. Miyoshi H, Ohshima K. Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan. Int J Hematol. 2018;107(4):420–7.

    Article  CAS  PubMed  Google Scholar 

  5. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia–lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol. 1991;79(3):428–37.

    Article  CAS  PubMed  Google Scholar 

  6. Shimoyama M. Chemotherapy of ATL. In: Takatsuki K, editor. Adult T-cell leukemia. Oxford University Press: Oxford; 1994. p. 221–237.

    Google Scholar 

  7. Satake M, et al. Incidence of human T-lymphotropic virus 1 infection in adolescent and adult blood donors in Japan: a nationwide retrospective cohort analysis. Lancet Infect Dis. 2016;16(11):1246–54.

    Article  PubMed  Google Scholar 

  8. Nosaka K, et al. Epidemiological and clinical features of adult T-cell leukemia–lymphoma in Japan, 2010–2011: a nationwide survey. Cancer Sci. 2017;108(12):2478–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Matsushita K, et al. Long-term maintenance combination chemotherapy with OPEC/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia/lymphoma. Leuk Lymphoma. 1999;36(1–2):67–75.

    Article  CAS  PubMed  Google Scholar 

  10. Tsukasaki K, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia–lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458–64.

    Article  CAS  PubMed  Google Scholar 

  11. Tsukasaki K, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia–lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27(3):453–9.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.

    Article  CAS  PubMed  Google Scholar 

  13. Katsuya H, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012;30(14):1635–40.

    Article  CAS  PubMed  Google Scholar 

  14. Yamada Y, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia–lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113(2):375–82.

    Article  CAS  PubMed  Google Scholar 

  15. Makiyama J, et al. Treatment outcome of elderly patients with aggressive adult T cell leukemia–lymphoma: Nagasaki University Hospital experience. Int J Hematol. 2014;100(5):464–72.

    Article  CAS  PubMed  Google Scholar 

  16. Ishida T, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia–lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837–42.

    Article  CAS  PubMed  Google Scholar 

  17. Ishida T, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma: ATLL-002. J Clin Oncol. 2016;34(34):4086–93.

    Article  CAS  PubMed  Google Scholar 

  18. Ishida T, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia–lymphoma: a randomized phase II study. Br J Haematol. 2015;169(5):672–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Izuro Imamura Hospital, 17-1 Horie, Kagoshima, Japan

    Daisuke Nakamura, Tomohisa Tabuchi, Naosuke Arima, Maiko Hayashida, Hirosaka Inoue, Kakushi Matsushita & Tadashi Matsumoto

  2. Department of Hematology and Rheumatology, Kagoshima University Hospital, 8-35-1 Sakuragaoka, Kagoshima, Japan

    Daisuke Nakamura, Makoto Yoshimitsu, Tomohisa Tabuchi, Naosuke Arima, Maiko Hayashida, Hirosaka Inoue, Kakushi Matsushita, Naomichi Arima & Kenji Ishitsuka

Authors
  1. Daisuke Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Makoto Yoshimitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomohisa Tabuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naosuke Arima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maiko Hayashida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hirosaka Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kakushi Matsushita
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tadashi Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Naomichi Arima
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kenji Ishitsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daisuke Nakamura.

Ethics declarations

Conflict of interest

No potential conflict of interest was reported by the authors for this manuscript.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakamura, D., Yoshimitsu, M., Tabuchi, T. et al. Treatment of aggressive adult T-cell leukemia/lymphoma: a retrospective study in a hospital located in HTLV-1 highly endemic area. Int J Hematol 111, 234–240 (2020). https://doi.org/10.1007/s12185-019-02769-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-019-02769-w

Keywords

Search

Navigation